MedTrace Logo

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

NCT01507545 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2022-05-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate whether therapy with MORAb-004 is effective and safe in the treatment of metastatic, colorectal cancer.

Conditions

Interventions

DRUG

MORAb-004

MORAb-004 8mg per kg IV once a week

DRUG

Placebo

Placebo - normal saline IV once a week

OTHER

Best supportive care

Best supportive care to improve quality of life

Sponsors & Collaborators

  • Morphotek

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-27
Primary Completion
2013-10-20
Completion
2013-10-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01507545 on ClinicalTrials.gov